Efficacy and safety of Privigen^®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura

By Robak T.   Salama A.   Kovaleva L.   Vyhovska Y.   Davies S. V.   Mazzucconi M. G.   Zenker O.   Kiessling P.    

Hematology, Vol. 14, Iss. 4, 2009-08 ,pp. : 227-236

Maney Publishing

Access to resources Recommend Favorite

Safety and Tolerability of Increased Rate of Infusion of Intravenous Immunoglobulin G, 10% in Antibody-Deficient Patients

By Gelfand Erwin   Hanna Kim  

Journal of Clinical Immunology, Vol. 26, Iss. 3, 2006-05 ,pp. : 284-290

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac^®) in chronic immune thrombocytopenic purpura

By Aledort L. M.   Salama A.   Kovaleva L.   Robak T.   Newland A. C.   Nugent D. J.   Brenner B.   Zenker O.  

Hematology, Vol. 12, Iss. 4, 2007-08 ,pp. : 289-295

Maney Publishing

Access to resources Recommend Favorite

Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates

By Sleasman John   Duff Carla   Dunaway Theresa   Rojavin Mikhail   Stein Mark  

Journal of Clinical Immunology, Vol. 30, Iss. 3, 2010-05 ,pp. : 442-448

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and Tolerability of an Argentine Intravenous Immunoglobulin in Pediatric Patients with Primary Immunodeficiency Diseases

By Krasovec S.   Ornani A.   Oleastro M.   Rosenzweig S.   Roy A.   Perez L.   Campos G.   MarÍn N.   Martinez A.   Mahieu C.   Manfredi M.   Sisti A.   Zelazko M.  

Journal of Clinical Immunology, Vol. 27, Iss. 2, 2007-03 ,pp. : 227-232

Springer Publishing Company

Access to resources Recommend Favorite